Follow The Filings

Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,839 companies covered, latest filing Oct 23.

  • $1.5B bought by 341 insiders at 208 companies
  • $3.2B sold by 266 insiders outside a trading plan
  • $7.9B sold by 827 insiders under 10b5-1 plans
  • 10 companies where two or more insiders bought (30 days)

Biggest buys

Past month, each insider's filings added up.

  1. LENLennar
    Berkshire Hathaway Inc.10% owner, +1 joint filer
    4,758,747 shares at $80.46 Sep 23–Oct 2, 3 filings 3 superinvestors bought in Q2
    $383M
  2. CRBGCorebridge Financial
    Life Insurance Co Nippon10% owner
    6,596,299 shares at $34.18 Sep 21–Oct 20, 21 filings +5.3% to stake 2 superinvestors bought in Q2
    $225M
  3. KODKodiak Sciences
    Baker Bros. Advisors LPDirector, +5 joint filers
    1,941,755 shares at $80.85 Sep 28–29, 3 filings +11% to stake 1 superinvestor sold in Q2
    $157M
  4. SAFXXCF Global
    EEME Energy SPV I, LLC10% owner
    119M shares at $1.19 Oct 16 +109% to stake
    $142M
  5. GPIGroup 1 Automotive
    Conifer Management, L.L.C.10% owner
    400,000 shares at $244.51 Sep 24–30, 2 filings +26% to stake 2 superinvestors bought in Q2
    $97.8M
  6. UUUUniversal Safety Products
    Milton C Ault IIIDirector
    33,434 shares at $2,766.36 Sep 21–30, 2 filings
    $92.5M
  7. GMEGameStop
    Ryan CohenCEO
    1,994,130 shares at $25.29 Sep 29–Oct 13, 3 filings +4.9% to stake
    $50.4M
  8. BORRBorr Drilling
    Tor Olav TroimDirector
    9,500,000 shares at $4.53 Oct 5–15, 7 filings +31% to stake
    $43M
  9. PAMPampa Energia
    Marcos Marcelo MindlinDirector
    435,000 shares at $80.78 Oct 15 +6.4% to stake
    $35.1M
  10. GGRGogoro
    Chung-Yao YinDirector
    14.2M shares at $2.48 Oct 7 New stake
    $35.1M

Biggest sales

Past month, each insider's filings added up. Planned sales are marked.

  1. IHTInnSuites Hospitality Trust
    James F WirthCEO
    86,222 shares at $48,532.59 Oct 7–20, 2 filings 1.1% of stake Planned sale (10b5-1)
    $4.2B
  2. MDLNMedline
    GIC Private Ltd10% owner, +2 joint filers
    28.5M shares at $34.97 Oct 2–8, 2 filings
    $996M
  3. ESTCElastic
    Steven SchuurmanDirector
    3,500,000 shares at $92.43 Oct 5–12, 2 filings 58% of stake
    $323M
  4. TALOTalos Energy
    Empresarial De Capitales S.a. De C.v. Control10% owner
    14.6M shares at $17.33 Oct 6–19, 5 filings 37% of stake
    $253M
  5. AVGOBroadcom
    Henry SamueliDirector
    702,190 shares at $356.04 Sep 23 1.9% of stake Planned sale (10b5-1)
    $250M
  6. THTarget Hospitality
    TDR Capital II Investments LP10% owner, +9 joint filers
    11M shares at $18.40 Oct 1 40% of stake
    $202M
  7. ANETArista Networks
    Jayshree UllalCEO
    778,531 shares at $213.68 Sep 25–Oct 9, 4 filings 4.8% of stake Planned sale (10b5-1)
    $166M
  8. KNTKKinetik
    ISQ Global Fund II GP LLC10% owner, +4 joint filers
    2,448,272 shares at $54.63 Sep 22–Oct 13, 4 filings 100% of stake
    $134M
  9. CRWDCrowdStrike
    Burt W. PodbereCFO
    480,000 shares at $261.44 Sep 24 Planned sale (10b5-1)
    $125M
  10. NBISNebius Group
    Ophir NaveCOO
    500,000 shares at $235.53 Oct 5 52% of stake Planned sale (10b5-1)
    $118M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

  1. TSMTaiwan Semiconductor 19 insiders, $80K

    Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

    Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
  2. SPGSimon Property Group 11 insiders, $461K

    Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

    Latest buy Sep 30
  3. FULH. B. Fuller 9 insiders, $1.1M

    R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

    Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
  4. RAPPRapport Therapeutics 5 insiders, $1.6M

    Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +1 more

    Latest buy Oct 22 1 executive
  5. ATCHAtlasClear 5 insiders, $163K

    Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

    Latest buy Sep 25 3 executives
  6. RGCORGC Resources 5 insiders, $85K

    John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

    Latest buy Oct 1 3 executives
  7. WVVIWillamette Valley Vineyards 5 insiders, $75K

    Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

    Latest buy Oct 12 3 executives
  8. MPBMid Penn Bancorp 5 insiders, $25K

    Matthew G De Soto Director, Albert J. Evans Director, Kimberly J Brumbaugh Director, Theodore W Mowery Director, +1 more

    Latest buy Sep 30
  9. DXDynex Capital 4 insiders, $245K

    Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

    Latest buy Oct 20 4 executives
  10. ANIXAnixa Biosciences 4 insiders, $203K

    Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

    Latest buy Oct 22 2 executives

MEDP insider trades

Every open-market buy and sale in MEDP, one row per filing, newest first

MEDP page
All Buys Sales
Everyone CEOs CFOs Executives Directors 10% owners
Any size $100K+ $1M+ $10M+
Hide planned sales
  1. August J. Troendle CEO
    MEDPMedpace
    Sale
    $30.3M 48,667 shares at $623.03 13% of stake
    Traded Sep 29–30 Filed Oct 1
    ↗
  2. August J. Troendle CEO
    MEDPMedpace
    Sale
    $1.6M 2,564 shares at $620.10 0.7% of stake
    Traded Sep 25–28 Filed Sep 29
    ↗
  3. August J. Troendle CEO
    MEDPMedpace
    Sale
    $27.4M 43,916 shares at $624.01 10% of stake
    Traded Sep 23–24 Filed Sep 25
    ↗
  4. August J. Troendle CEO
    MEDPMedpace
    Sale
    $44.4M 70,901 shares at $626.62 14% of stake
    Traded Sep 21–22 Filed Sep 23
    ↗
  5. August J. Troendle CEO
    MEDPMedpace
    Sale
    $6.7M 10,880 shares at $620.40 2.1% of stake
    Traded Sep 17 Filed Sep 21
    ↗
  6. August J. Troendle CEO
    MEDPMedpace
    Sale
    $15.4M 24,741 shares at $621.00 4.6% of stake
    Traded Sep 15–16 Filed Sep 17
    ↗
  7. August J. Troendle CEO
    MEDPMedpace
    Sale
    $403K 650 shares at $620.27 0.1% of stake
    Traded Aug 27 Filed Aug 31
    ↗
  8. Robert O. Kraft Director
    MEDPMedpace
    Sale
    $2.4M 3,858 shares at $617.81 80% of stake
    Traded Aug 26 Filed Aug 28
    ↗
  9. August J. Troendle CEO
    MEDPMedpace
    Sale
    $2.9M 4,673 shares at $620.08 0.9% of stake
    Traded Aug 25–26 Filed Aug 27
    ↗
  10. August J. Troendle CEO
    MEDPMedpace
    Sale
    $10M 15,978 shares at $623.93 2.8% of stake
    Traded Aug 21–24 Filed Aug 25
    ↗
  11. Kevin M. Brady CFO
    MEDPMedpace
    Sale
    $2.1M 3,400 shares at $625.24 21% of stake
    Traded Aug 20 Filed Aug 24
    ↗
  12. August J. Troendle CEO
    MEDPMedpace
    Sale
    $26.3M 42,783 shares at $614.30 7.1% of stake
    Traded Aug 19–20 Filed Aug 21
    ↗
  13. Brian T Carley Director
    MEDPMedpace
    Sale
    $3M 5,000 shares at $608.63 15% of stake
    Traded Aug 19 Filed Aug 21
    ↗
  14. Fred B Davenport Jr. Director
    MEDPMedpace
    Sale
    $4.4M 7,283 shares at $606.15 66% of stake
    Traded Aug 19 Filed Aug 21
    ↗
  15. August J. Troendle CEO
    MEDPMedpace
    Sale
    $7.1M 11,824 shares at $601.49 1.9% of stake
    Traded Aug 12–13 Filed Aug 14
    ↗
  16. Cornelius P. McCarthy III Director
    MEDPMedpace
    Sale
    $690K 1,140 shares at $605.37 8.5% of stake
    Traded Aug 11 Filed Aug 13
    ↗
  17. August J. Troendle CEO
    MEDPMedpace
    Sale
    $14M 23,144 shares at $604.25 3.6% of stake
    Traded Aug 10–11 Filed Aug 12
    ↗
  18. Cornelius P. McCarthy III Director
    MEDPMedpace
    Sale
    $465K 795 shares at $585.07 5.6% of stake
    Traded Aug 7 Filed Aug 11
    ↗
  19. August J. Troendle CEO
    MEDPMedpace
    Sale
    $4.3M 7,238 shares at $600.44 1.1% of stake
    Traded Jul 27–28 Filed Jul 29
    ↗
  20. Susan E Burwig Exec. VP, Operations
    MEDPMedpace
    Sale
    $4.5M 7,500 shares at $600.00 11% of stake
    Traded Jul 28 Filed Jul 29
    ↗
  21. Stephen P Ewald General Counsel & Corp. Secy.
    MEDPMedpace
    Sale
    $7.4M 16,349 shares at $450.00 45% of stake
    Traded May 28 Filed Jun 1
    ↗
  22. Jesse J Geiger President
    MEDPMedpace
    Sale
    $14.4M 31,707 shares at $455.30 68% of stake
    Traded Mar 17 Filed Mar 19
    ↗
  23. August J. Troendle CEO
    MEDPMedpace
    Sale
    $395K 668 shares at $590.69 0.1% of stake
    Traded Dec 3, 2025 Filed Dec 4, 2025
    ↗
  24. August J. Troendle CEO
    MEDPMedpace
    Sale
    $17.1M 28,876 shares at $592.70 4.3% of stake
    Traded Dec 1–2 Filed Dec 3, 2025
    ↗
  25. August J. Troendle CEO
    MEDPMedpace
    Sale
    $34.1M 56,482 shares at $603.28 7.7% of stake
    Traded Nov 26–28 Filed Dec 1, 2025
    ↗
  26. August J. Troendle CEO
    MEDPMedpace
    Sale
    $62M 101,417 shares at $611.02 12% of stake
    Traded Nov 24–25 Filed Nov 26, 2025
    ↗
  27. Susan E Burwig Exec. VP, Operations
    MEDPMedpace
    Sale
    $12.2M 20,000 shares at $609.15 42% of stake
    Traded Nov 24, 2025 Filed Nov 26, 2025
    ↗
  28. Kevin M. Brady CFO
    MEDPMedpace
    Sale
    $1.8M 3,000 shares at $590.35 33% of stake
    Traded Nov 21, 2025 Filed Nov 25, 2025
    ↗
  29. August J. Troendle CEO
    MEDPMedpace
    Sale
    $17M 28,688 shares at $593.68 3.3% of stake
    Traded Nov 20–21 Filed Nov 24, 2025
    ↗
  30. August J. Troendle CEO
    MEDPMedpace
    Sale
    $18.4M 31,053 shares at $591.79 3.5% of stake
    Traded Nov 18–19 Filed Nov 20, 2025
    ↗
  31. Robert O. Kraft Director
    MEDPMedpace
    Sale
    $3.8M 6,472 shares at $591.85 89% of stake
    Traded Nov 14, 2025 Filed Nov 18, 2025
    ↗
  32. August J. Troendle CEO
    MEDPMedpace
    Sale
    $12.4M 20,794 shares at $594.02 2.3% of stake
    Traded Nov 14–17 Filed Nov 18, 2025
    ↗
  33. August J. Troendle CEO
    MEDPMedpace
    Sale
    $6.3M 10,440 shares at $602.32 1.1% of stake
    Traded Nov 12–13 Filed Nov 14, 2025
    ↗
  34. Susan E Burwig Exec. VP, Operations
    MEDPMedpace
    Sale
    $10.9M 18,000 shares at $605.00 28% of stake
    Traded Nov 11, 2025 Filed Nov 12, 2025
    ↗
  35. Jesse J Geiger President
    MEDPMedpace
    Planned sale
    $12.8M 21,503 shares at $595.66 59% of stake
    Traded Nov 5, 2025 Filed Nov 7, 2025
    ↗
  36. Fred B Davenport Jr. Director
    MEDPMedpace
    Sale
    $3.5M 5,972 shares at $581.88 63% of stake
    Traded Oct 30, 2025 Filed Nov 3, 2025
    ↗
  37. Jesse J Geiger President
    MEDPMedpace
    Sale
    $13.9M 23,028 shares at $602.00 39% of stake
    Traded Oct 27–29 Filed Oct 29, 2025
    ↗
  38. Stephen P Ewald General Counsel & Corp. Secy.
    MEDPMedpace
    Sale
    $9.1M 15,230 shares at $598.85 53% of stake
    Traded Oct 27, 2025 Filed Oct 29, 2025
    ↗
  39. Susan E Burwig Exec. VP, Operations
    MEDPMedpace
    Sale
    $1.2M 2,000 shares at $605.01 3% of stake
    Traded Oct 27, 2025 Filed Oct 29, 2025
    ↗

About this data

  • Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
  • Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
  • A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
  • Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
  • We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.